acidbas
abnorm
mucos
integr
organ
function
inflammatori
respons
immedi
therapeut
intervent
often
absenc
definit
diagnosi
reduc
comorbid
mortal
hematolog
abnorm
seen
earli
cours
gastrointestin
diseas
reflect
stress
endotoxemia
leukopenia
may
character
lymphopenia
neutropenia
without
left
shift
toxic
chang
neutrophil
neutrophil
leukocytosi
may
seen
later
degen
left
shift
presenc
metamyelocyt
myelocyt
poor
prognost
indic
hemoconcentr
thrombocytopenia
common
hors
pack
cell
volum
greater
time
less
like
surviv
hyperfibrinogenemia
elev
serum
amyloid
may
seen
acut
sever
coliti
diarrhea
hors
associ
hemodynam
electrolyt
chang
caus
intralumin
sequestr
fluid
serum
biochemistri
often
reveal
renal
preren
azotemia
electrolyt
abnorm
includ
hyponatremia
hypochloremia
hypokalemia
hypocalcemia
one
retrospect
neg
base
excess
best
prognost
indic
studi
hors
plasma
lactat
admiss
associ
surviv
statu
howev
reduct
serial
lactat
concentr
greater
equal
hour
greater
equal
hour
admiss
significantli
associ
surviv
creatinin
concentr
greater
mgdl
mmoll
also
associ
lower
likelihood
surviv
hyperproteinemia
may
present
sever
dehydr
although
mild
sever
hypoproteinemia
also
seen
result
gastrointestin
protein
loss
abdomin
ultrasonographi
import
diagnost
aid
case
acut
diarrhea
perform
assess
larg
small
intestin
wall
thick
periton
fluid
volum
charact
see
nicola
c
cribb
lui
g
arroyo
articl
techniqu
accuraci
abdomin
ultrasound
gastrointestin
diseas
hors
foal
issu
detail
commerci
laboratori
frequent
offer
diarrhea
panel
help
screen
numer
pathogen
howev
like
screen
test
specif
may
compromis
result
interpret
caution
furthermor
diagnost
laboratori
includ
test
unnecessari
clinic
relev
adult
hors
tabl
provid
summari
commerci
avail
fecal
serolog
diagnost
limit
salmonellosi
wellrecogn
caus
acut
diarrhea
hors
report
result
infect
salmonella
enterica
subsp
enterica
g
facult
anaerob
bacterium
numer
serovar
associ
clinic
diseas
salmonella
typhimurium
commonli
isol
diarrheic
hors
associ
high
pathogen
salmonella
infect
adult
hors
rang
inappar
carrier
state
pyrexia
anorexia
leukopenia
depress
without
diarrhea
acut
sever
enterocol
diarrhea
clinic
appar
salmonellosi
adult
hors
commonli
manifest
enterocol
largevolum
wateri
diarrhea
subsequ
bacteremia
profound
neutropenia
characterist
salmonella
infect
result
neutrophil
margin
invas
intestin
villi
loss
intestin
lumen
intestin
mucos
damag
permit
bacteri
entri
portal
circul
potenti
damag
hepatocyt
increas
serum
level
sorbitol
dehydrogenas
aspart
transaminas
dehydr
sever
associ
preren
quick
highli
sensit
falseposit
occur
detect
carrier
common
popul
cultur
low
diagnost
yield
common
shed
healthi
hors
cultur
pcr
pcr
detect
select
toxin
gene
increas
diagnost
relev
particularli
gene
commonli
associ
diseas
eg
netf
toxinelisa
current
restrict
enterotoxin
posit
result
suggest
enterotoxin
detect
healthi
hors
pcr
genotyp
avail
special
laboratori
fecal
pcr
epidemiolog
ecov
well
establish
posit
result
hors
diseas
consist
ecov
infect
provid
presumpt
diagnosi
fecal
blood
pcr
detect
blood
may
sensit
earli
cours
diseas
hors
becom
pcr
posit
fece
later
serolog
ifa
singl
serum
sampl
diagnost
abbrevi
ecov
equin
coronaviru
elisa
enzymelink
immunosorb
assay
ifa
indirect
fluoresc
antibodi
pcr
polymeras
chain
reaction
tcda
c
difficil
toxin
tcdb
c
difficil
toxin
b
azotemia
decreas
blood
ph
clinic
sign
pyrexia
inappet
diarrhea
colic
larg
result
host
inflammatori
respons
risk
factor
infect
includ
recent
abdomin
surgeri
antimicrobi
administr
transport
gastrointestin
diseas
immunosuppress
diet
chang
respiratori
diseas
high
ambient
temperatur
gener
anesthesia
histor
diagnosi
salmonella
coliti
made
identif
organ
fecal
cultur
intermitt
shed
realtim
quantit
polymeras
chain
reaction
qpcr
larg
replac
cultur
base
shorter
time
result
increas
rel
sensit
potenti
fewer
serial
sampl
requir
detect
salmonella
three
five
serial
fecal
sampl
pcr
cultur
depend
laboratori
method
recommend
determin
neg
salmonella
statu
treatment
earli
diseas
mainli
support
intraven
isoton
fluid
direct
volum
replac
buy
time
tissu
recoveri
acidbas
electrolyt
abnorm
correct
inflamm
control
sever
leukopenia
frequent
occur
case
salmonella
infect
warrant
consider
antimicrobi
therapi
aminoglycosid
fluoroquinolon
cephalosporin
given
propens
organ
caus
microthrombosi
infarct
anticoagul
therapi
may
consid
nosocomi
salmonella
infect
hospit
biosecur
focu
recent
literatur
outbreak
teach
hospit
result
prolong
closur
signific
econom
loss
decreas
clinic
time
veterinari
student
strict
biosecur
measur
enforc
case
acut
diarrhea
prevent
potenti
nosocomi
spread
salmonella
spp
highli
infecti
organ
coliti
result
clostridium
difficil
infect
cdi
first
describ
hors
clostridium
perfringen
c
difficil
clostridi
speci
commonli
associ
diarrhea
sporad
case
attribut
clostridium
septicum
clostridium
sordelli
clostridium
cadaveri
c
difficil
common
isol
case
coliti
adult
hors
cdi
receiv
recent
attent
human
literatur
although
preval
ribotyp
respons
diseas
differ
human
anim
c
difficil
isol
manur
healthi
hors
preval
rate
rang
thu
carrier
state
hors
livestock
suggest
reservoir
human
cdi
import
risk
factor
cdi
adult
hors
antimicrobi
administr
hospit
isol
toxigen
c
difficil
associ
administr
antimicrobi
notabl
blactam
gentamicin
trimethoprim
sulfonamid
clindamycin
erythromycin
rifampicin
proton
pump
inhibitor
h
antagonist
implic
develop
cdi
hors
strong
evid
lack
import
virul
factor
c
difficil
toxin
tcda
enterotoxin
toxin
b
tcdb
cytotoxin
clinic
diseas
howev
occur
normal
gastrointestin
flora
disrupt
toxigen
strain
c
difficil
prolifer
human
cdi
acut
chronic
wherea
chronic
cdi
hors
describ
c
difficil
coliti
vari
peracut
coliti
rapid
declin
milder
prolong
cours
hors
may
pyrex
depress
anorex
develop
diarrhea
gastrointestin
sign
neutropenia
hypoproteinemia
dehydr
hemoconcentr
electrolyt
acidbas
abnorm
may
appreci
c
difficil
challeng
cultur
falseneg
test
result
possibl
cdi
therefor
like
underdiagnos
enzym
immunoassay
develop
identif
tcda
tcdb
although
perform
highli
variabl
recent
molecular
detect
method
follow
bacteri
cultur
use
identifi
gene
tcda
tcdb
fece
hors
asid
support
care
specif
treatment
cdi
remain
controversi
evid
exist
saccharomyc
boulardii
nonpathogen
yeast
destroy
tcda
ditrioctahedr
smectit
bind
tcda
tcdb
dosedepend
manner
vitro
may
use
limit
toxem
effect
toxin
metronidazol
commonli
use
treat
c
difficil
coliti
hors
reduc
c
difficil
popul
wherea
normal
flora
restor
although
metronidazol
resist
document
case
human
infect
preval
featur
equin
cdi
howev
even
target
antimicrobi
therapi
deleteri
effect
microbiota
may
disrupt
delay
recolon
benefici
bacteria
recent
fecal
transfaun
also
known
fecal
microbi
transplant
fecal
bacteriotherapi
reemerg
treatment
cdi
human
hors
proxim
duoden
infus
donor
fece
significantli
effect
standard
vancomycin
therapi
human
recurr
cdi
anecdot
evid
support
use
fecal
microbi
slurri
via
nasogastr
intub
treatment
acut
case
equin
cdi
investig
need
provid
evidencebas
support
c
perfringen
associ
occasion
case
acut
diarrhea
adult
hors
isol
gastrointestin
flora
normal
hors
although
report
preval
rate
low
rang
healthi
adult
hors
classifi
five
type
e
base
exotoxin
product
c
perfringen
type
isol
commonli
cultur
healthi
diarrheic
adult
hors
toxin
suspect
produc
subtyp
c
perfringen
type
associ
clinic
c
perfringen
infect
hors
coliti
btoxin
produc
type
b
c
direct
cytotox
effect
result
enterocyt
necrosi
mucos
ulcer
hemorrhag
diarrhea
enterotoxin
produc
type
type
c
strain
creat
pore
alter
membran
permeabl
lead
cell
necrosi
poreform
toxin
netf
also
recent
identifi
major
virul
determin
associ
necrot
enter
foal
dog
clinic
sign
c
perfringen
vari
peracut
fatal
coliti
milder
present
anorexia
depress
pyrexia
gastrointestin
sign
includ
profus
wateri
diarrhea
may
hemorrhag
affect
hors
demonstr
nonspecif
sign
colic
endotoxemia
dehydr
given
presenc
fece
normal
hors
diagnosi
c
perfringen
coliti
challeng
quantit
fecal
cultur
longer
support
diagnosi
c
perfringen
coliti
enzym
immunoassay
c
perfringen
enterotoxin
detect
presenc
healthi
clinic
affect
hors
recent
pcr
use
detect
toxin
gene
although
prove
causal
relat
therapi
mainli
support
specif
therapi
aim
bind
exotoxin
includ
treatment
ditrioctahedr
smectit
limit
evid
benefit
metronidazol
therapi
case
c
perfringen
coliti
equin
coronaviru
ecov
recent
emerg
signific
enter
pathogen
adult
hors
although
coronavirus
long
identifi
fece
infecti
acut
diarrhea
adult
hors
adult
hors
foal
role
pathogenesi
enter
fever
diarrhea
recent
elucid
outbreak
clinic
diseas
ecov
envelop
positivestrand
rna
viru
belong
genu
transmiss
believ
via
fecalor
rout
infect
begin
small
intestin
lesion
includ
necrosi
slough
enterocyt
intestin
villi
dilat
crypt
fill
necrot
debri
mucos
inflamm
hematolog
abnorm
includ
leukopenia
character
neutropenia
lymphopenia
common
clinic
manifest
ecov
infect
includ
anorexia
lethargi
fever
report
clinic
case
diarrhea
colic
seen
affect
hors
respect
neurolog
sign
associ
ecov
infect
describ
seem
associ
hyperammonem
encephalopathi
alzheim
type
ii
astrocytosi
cerebr
cortex
diagnosi
ecov
coliti
current
base
pcr
fece
gastrointestin
content
tissu
sampl
one
studi
signific
statist
differ
absolut
ecov
quantif
posit
sick
posit
healthi
hors
howev
overal
agreement
clinic
statu
hors
demonstr
clinic
sign
ecov
infect
ecovposit
statu
pcr
therapi
direct
support
care
prevent
hyperammonem
encephalopathi
potomac
hors
fever
phf
equin
neorickettsiosi
first
recogn
caus
acut
typhlocol
hors
unit
state
along
potomac
river
area
sinc
describ
canada
uruguay
brazil
europ
acut
potenti
fatal
diseas
infect
gramneg
oblig
intracellular
bacteri
endosymbiont
neorickettsia
risticii
bacterium
surviv
digen
trematod
acanthatrium
lecithodendrium
spp
trematod
use
freshwat
lymnaeid
snail
first
intermedi
host
aquat
insect
mayfli
caddisfli
damselfli
dragonfli
stonefli
second
intermedi
host
definit
host
trematod
brown
bat
eptesicu
fuscu
myoti
lucifugu
hors
becom
accident
host
digen
trematod
inadvert
ingest
infect
intermedi
host
n
risticii
releas
trematod
insid
equin
gastrointestin
tract
invad
replic
within
colon
epitheli
cell
also
transloc
blood
monocyt
equin
monocyt
ehrlichiosi
mast
cell
tissu
macrophag
season
rise
diseas
incid
seen
warmer
month
common
clinic
sign
phf
diarrhea
fever
anorexia
depress
colic
abort
may
also
occur
result
n
risticii
infect
one
retrospect
hors
phf
lamin
identifi
affect
four
feet
hors
present
clinicopatholog
abnorm
typic
seen
equin
coliti
studi
identifi
serum
creatinin
urea
nitrogen
concentr
hematocrit
red
blood
count
blood
hemoglobin
concentr
band
neutrophil
serum
aspart
transaminas
serum
ck
anion
gap
significantli
higher
nonsurvivor
serum
chlorid
serum
sodium
durat
hospit
significantli
lower
nonsurvivor
diagnost
phf
includ
serum
indirect
fluoresc
antibodi
test
enzymelink
immunosorb
assay
cultur
n
risticii
buffi
coat
fece
pcr
whole
blood
fece
exposur
vaccin
lead
mani
fals
posit
antibodi
test
one
studi
healthi
hors
rise
pair
indirect
fluoresc
antibodi
titer
antigen
test
recommend
cultur
n
risticii
remain
gold
standard
diagnosi
although
pcr
report
identifi
cultureposit
natur
infect
hors
tetracyclin
antibiot
effect
kill
n
risticii
oxytetracyclin
administr
hors
clinic
sign
diseas
posit
associ
surviv
addit
therapi
support
includ
fluid
replac
lamin
prevent
particular
attent
paid
fluid
resuscit
hypovolem
hors
either
conjunct
administr
nephrotox
drug
oxytetracyclin
nonsteroid
antiinflammatori
drug
nsaid
sever
kill
adjuv
vaccin
market
howev
vaccin
failur
rate
high
like
caus
antigen
differ
present
among
greater
n
rickettsia
strain
isol
clinic
case
fluid
therapi
gastrointestin
diseas
cover
depth
fluid
plan
base
clinic
clinicopatholog
assess
fluid
deficit
base
formula
volum
deficit
l
bwt
kg
dehydr
gener
accept
approach
replac
volum
deficit
rate
mlkgh
patient
reassess
everi
hour
chang
fluid
plan
made
accord
chang
hydrat
statu
mainten
requir
ongo
fluid
loss
also
calcul
administ
fluid
appropri
rate
mainten
fluid
volum
mlkg
per
hour
goal
fluid
therapi
volum
resuscit
correct
lactic
acidosi
commerci
avail
balanc
isoton
fluid
administ
fluid
supplement
decis
made
base
serum
electrolyt
acidbas
statu
lactic
acidosi
caus
dehydr
common
hypokalemia
common
anorect
hors
gastrointestin
diseas
address
serum
potassium
less
meql
sodium
bicarbon
supplement
consid
base
deficit
greater
meql
ph
less
requir
amount
sodium
bicarbon
administ
isoton
solut
period
hour
import
rememb
administr
sodium
bicarbon
correct
metabol
acidosi
lactic
acidosi
secondari
dehydr
therefor
sodium
bicarbon
use
adjunct
therapi
balanc
isoton
fluid
metabol
acidosi
sever
amount
sodium
bicarbon
requir
estim
use
follow
formula
ioniz
calcium
level
less
mgdl
mmoll
decreas
intestin
motil
indic
calcium
supplement
gener
indic
use
colloid
includ
hypovolemia
hyproteinemia
decreas
osmot
pressur
hypoproteinemia
common
hors
diarrhea
synthet
colloid
commerci
equin
plasma
often
administ
literatur
evalu
use
synthet
colloid
hors
limit
experiment
studi
small
popul
clinic
evalu
hydroxyethyl
starch
he
increas
colloid
osmot
pressur
cop
normal
poni
dosedepend
effect
hemostat
variabl
lead
trend
prolong
bleed
time
hypoproteinem
hors
he
modest
effect
cop
administ
typic
dose
restor
cop
normal
experiment
endotoxemia
use
he
hyperton
salin
solut
exert
benefit
cardiac
output
system
vascular
resist
compar
isoton
fluid
resuscit
furthermor
signific
differ
coagul
measur
note
hors
treat
he
versu
isoton
fluid
howev
he
shown
advers
affect
platelet
function
vitro
healthi
hors
use
synthet
colloid
crystalloid
human
patient
sepsi
question
colloid
administr
associ
acut
kidney
injuri
osmot
nephrosi
hemorrhag
anaphylactoid
reaction
tissu
accumul
hepat
organ
failur
pruritu
despit
numer
random
clinic
trial
metaanalys
conflict
evid
correl
colloid
administr
increas
mortal
rate
increas
need
renalreplac
therapi
howev
surviv
sepsi
campaign
recommend
use
he
sepsi
result
european
medicin
agenc
conclud
he
solut
use
patient
sepsi
critic
ill
patient
food
drug
administr
place
box
warn
he
increas
mortal
renalreplac
therapi
recent
studi
compar
effect
he
versu
commerci
equin
plasma
clinicopatholog
valu
cop
healthi
hors
reveal
product
produc
equival
although
modest
increas
plasma
cop
meanwhil
plasma
less
profound
less
prolong
dilut
effect
hematocrit
blood
hemoglobin
serum
total
protein
albumin
concentr
compar
he
benefit
he
plasma
includ
lower
cost
easier
storag
higher
oncot
pressur
risk
infecti
diseas
transmiss
howev
equin
plasma
provid
immunoglobulin
coagul
factor
antithrombin
plasma
may
also
less
like
result
acut
kidney
injuri
coagul
abnorm
critic
ill
patient
although
evid
human
literatur
appli
equin
medicin
need
evalu
he
use
critic
ill
septic
hors
meantim
judici
use
colloid
patient
recommend
advantag
disadvantag
antimicrobi
administr
consid
use
case
acut
diarrhea
one
retrospect
hors
present
coliti
previous
treat
antimicrobi
time
less
like
surviv
treat
antimicrobi
use
affect
fecal
microbiota
like
alreadi
disturb
procain
penicillin
ceftiofur
sodium
trimethoprim
sulfadiazin
administr
impact
fecal
microbiota
healthi
hors
chang
often
persist
day
identif
clinic
suspicion
presenc
certain
pathogen
warrant
target
antimicrobi
use
oxytetracyclin
consid
treatment
choic
hors
phf
metronidazol
recommend
treatment
c
difficileassoci
diarrhea
cdad
human
often
use
treat
hors
confirm
presum
cdad
howev
magdesian
colleagu
demonstr
associ
metronidazol
administr
identif
metronidazoleresist
c
difficil
strain
although
metronidazol
resist
hors
cdi
consid
clinic
import
time
strain
suspect
virul
effect
hors
metronidazoleresist
strain
c
difficil
increas
risk
mortal
compar
hors
infect
metronidazolesuscept
strain
antimicrobi
therapi
may
warrant
acut
diarrhea
case
demonstr
sever
neutropenia
andor
evid
septic
foci
lung
liver
jugular
vein
antimicrobi
drug
select
base
cultur
suscept
pattern
caus
agent
whenev
possibl
howev
case
acut
undifferenti
diarrhea
hors
antibiot
may
contraind
disrupt
microbiota
furthermor
increas
shed
salmonella
associ
administr
antimicrobi
multidrug
resist
salmonella
spp
emerg
threat
therefor
judici
use
system
antimicrobi
strongli
recommend
effort
made
limit
endotoxin
entri
circul
reduc
releas
inflammatori
mediat
neutral
circul
endotoxin
provid
support
care
nsaid
inhibit
cyclooxygenas
enzym
associ
earli
hemodynam
respons
endotoxin
flunixin
meglumin
ketoprofen
significantli
decreas
product
thromboxan
b
product
blood
monocyt
vitro
low
dose
flunixin
meglumin
mgkg
suppress
thromboxan
prostaglandin
product
hors
challeng
endotoxin
although
dose
mgkg
also
antiendotox
lower
dose
may
associ
fewer
side
effect
especi
case
renal
insuffici
administr
nsaid
hors
endotoxemia
mainstay
treatment
albeit
practic
treatment
initi
follow
challeng
endogen
endotoxin
wherea
experiment
benefit
note
nsaid
administ
endotoxin
exposur
clinician
often
administ
flunixin
meglumin
everi
hour
control
clinic
sign
endotoxemia
limit
advers
side
effect
renal
papillari
necrosi
gastrointestin
ulcer
polymyxin
b
cation
polypeptid
antibiot
form
stabl
complex
lipid
compon
lipopolysaccharid
bound
lipopolysaccharid
interact
equin
inflammatori
cell
thu
prevent
initi
proinflammatori
cascad
initi
high
dose
reportedli
produc
sign
neurotox
nephrotox
administ
healthi
hors
dose
iukg
polymyxin
b
inhibit
endotoxininduc
tumor
necrosi
factor
activ
alter
either
creatinin
urin
gglutamyltransferasetocreatinin
ratio
note
howev
polymyxin
b
use
caution
hypovolem
azotem
anim
alway
administ
dilut
isoton
fluid
side
effect
neuromuscular
blockag
neurolog
side
effect
occur
administr
discontinu
hyperimmun
plasma
serum
deriv
hors
immun
gbacteria
endotoxin
propos
benefit
neutral
endotoxin
modul
leukocyt
activ
howev
conflict
evid
benefit
administr
hyperimmun
plasma
experiment
model
endotoxemia
hors
recent
studi
reveal
pretreat
hyperimmun
equin
plasma
fail
modifi
clinic
sign
experiment
induc
endotoxemia
impact
leukocyt
activ
reduc
bioactiv
tumor
necrosi
factora
studi
need
evalu
clinic
benefit
hyperimmun
plasma
serum
endotoxem
hors
pentoxifyllin
methyxanthin
deriv
increas
deform
red
blood
cell
suppress
product
proinflammatori
cytokin
inhibit
infecti
acut
diarrhea
adult
hors
activ
b
cell
experiment
pentoxifyllin
administr
limit
benefici
effect
endotoxem
hors
slight
benefit
combin
therapi
flunixin
meglumin
pentoxifyllin
commonli
use
hors
lamin
placent
increas
microvascular
blood
flow
current
publish
control
clinic
trial
support
use
theori
bind
exotoxin
endotoxin
within
gut
lumen
may
decreas
system
absorpt
hors
coliti
ditrioctaheadr
smectit
neg
charg
hydrat
aluminomagnesium
bind
posit
charg
organ
cation
dosedepend
bind
ditrioctaheadr
smectit
c
difficil
toxin
b
c
perfringen
enterotoxin
endotoxin
demonstr
vitro
recommend
dose
load
dose
follow
g
everi
hour
necessit
frequent
nasogastr
intub
activ
charcoal
nonspecif
bind
agent
use
mani
monogastr
speci
recent
vitro
studi
demonstr
signific
effect
activ
charcoal
microbi
popul
major
metabolit
produc
rate
ga
product
ph
valu
find
suggest
impact
activ
charcoal
equin
hindgut
bind
toxic
substanc
may
minim
vivo
studi
need
elucid
benefit
bind
agent
probiot
discuss
elsewher
issu
one
studi
hors
diarrhea
administr
boulardii
decreas
durat
diarrhea
day
compar
control
hors
contrast
signific
differ
return
normal
manur
return
normal
heart
rate
appetit
improv
clinic
variabl
measur
saccharomycestr
control
hors
random
prospect
studi
administr
lactobacillillu
spp
bifidobacterium
animali
lacti
impact
clostridi
shed
minim
impact
composit
fecal
microbiota
foal
administ
week
recent
literatur
suggest
oral
administ
probiot
pediococcu
acidilactici
boulardii
may
immunomodulatori
effect
hors
time
conflict
evid
regard
clinic
benefit
probiot
administr
furthermor
label
claim
veterinari
probiot
prepar
often
contain
gross
inaccuraci
qualiti
control
product
lack
addit
support
care
measur
gastroprotect
omeprazol
h
antagonist
often
use
prophylact
prevent
gastric
ulcer
anorect
hors
acut
diarrhea
proton
pump
inhibitor
administr
long
suspect
risk
factor
cdad
human
although
highqual
evid
causeeffect
relationship
lack
foal
treat
antiulc
medic
two
time
like
develop
diarrhea
left
untreat
associ
cdi
relationship
antiulc
medic
diarrhea
cdad
adult
hors
unknown
increas
gastric
ph
may
elimin
defens
c
difficil
pathogen
lamin
commonli
encount
case
sepsi
current
distal
limb
cryotherapi
appli
hoof
carpu
hour
continu
method
prevent
lamin
hors
system
inflamm
valid
feasibl
lamin
prevent
techniqu
includ
treat
primari
diseas
process
antiinflammatori
therapi
nsaid
pentoxifyllin
inhibit
neutrophil
platelet
margin
lowmolecularweight
heparin
pentoxifyllin
aspirin
possibl
corticosteroid
antioxid
therapi
dimethyl
sulfoxid
physic
support
sole
eas
breakov
bacteri
sepsi
potenti
lead
dissemin
intravascular
coagul
secondari
widespread
inflamm
salmonellosi
associ
thrombot
event
ewe
dissemin
intravascular
coagul
hors
control
clinic
trial
human
sepsi
heparin
improv
hypercoagul
state
reduc
time
intens
care
unit
decreas
day
mechan
ventil
retrospect
studi
hors
underw
colic
surgeri
preval
grade
lamin
lower
hors
treat
lowmolecularweight
heparin
although
unfract
heparin
often
use
prophylaxi
coagul
disord
lowmolecularweight
heparin
associ
fewer
side
effect
decreas
pack
cell
volum
pcv
cathetersit
complic
decreas
platelet
count
base
limit
data
heparin
therapi
may
indic
prophylact
measur
hors
sever
sepsi
nutrit
support
improv
outcom
critic
ill
human
small
anim
patient
hors
acut
coliti
typhlocol
often
partial
complet
anorex
result
ileu
dysmotil
hypoperfus
system
inflammatori
respons
lowbulk
diet
complet
pellet
feed
goodqual
grass
hay
alfalfa
recommend
hors
acut
coliti
offer
fresh
grass
may
stimul
appetit
anorect
hors
although
larg
amount
grass
may
contribut
develop
lamin
colic
sign
parenter
nutrit
benefici
sever
catabol
case
acut
coliti
toler
enter
feed
parenter
nutrit
indic
diarrheic
patient
anorexia
persist
hour
pregnant
lactat
mare
caus
acut
infecti
diarrhea
adult
hors
often
difficult
defin
howev
aim
therapi
univers
prompt
intervent
decreas
morbid
mortal
furthermor
strong
evid
support
mani
common
therapeut
option
lack
consid
construct
treatment
plan
